PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.

Published by Nathan Holland on

To consider the polymerase chain response (PCR)-reverse-dot-blot (RDB) human papillomavirus (HPV) genotyping test as a possible assay for the cervical cancer primary screening.In a hospital-based cohort, a complete of 21,568 ladies have been voluntarily enrolled from March 2009 to November 2016 for evaluating the three present cervical cancer screening methods: co-test, cytology primary and high-risk HPV (HR-HPV) primary through the use of PCR-RDB HPV genotyping and liquid-based cytology (thinprep cytologic test [TCT]).

 

Women with HR-HPV an infection and/or irregular cytology have been referred for colposcopy, and the biopsy or conization was carried out in line with the American Society for Colposcopy and Cervical Pathology (ASCCP) tips.Overall, 18.20% (3,935/21,568) of the ladies have been detected as HR-HPV-positive, 5.04% (1,088/21,568) have been recognized with cervical intraepithelial neoplasia 2 or greater (CIN2+), and three.43% (739/21,568) with CIN3+.

The cumulative incidence charges for CIN2+/CIN3+ in sufferers with HPV-16/18-positive have been 48.28%/37.20%, whereas they have been 0.86%/0.38%, 0.30%/0.15% and 0.18%/0.09% in cytology-negative, HR-HPV-negative and co-test-negative inhabitants, respectively. Using CIN2+ and CIN3+ as the noticed endpoints, the sensitivity and adverse predictive worth (NPV) of HR-HPV genotyping as a primary screening instrument have been 90.99%/99.49% and 91.57%/99.80%. Moreover, utilizing HR-HPV genotyping primary screening may detect the identical extra CIN2+/CIN3+ instances in baseline-detection as co-testing (990/700 vs. 991/701) and way over cytology primary screening (903/656, p<0.05).

It additionally achieved the bottom misdiagnosis price (8.01%/5.02%). Although HPV genotyping primary screening required an elevated variety of colposcopies (2.75/3.89 per CIN2+/CIN3+ case), it yielded an appropriate price.The PCR-RDB HPV genotyping test is a cost-effective and useful cervical cancer primary screening for hospital-based opportunistic screening.

PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.

PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.

Evaluation of dot-blottest for serological prognosis of bovine brucellosis.

The goal of this examine was to standardize and validate the dot-blot test for the serological prognosis of bovine brucellosis, evaluate the outcomes with these discovered in the 2-mercaptoethanol (2-ME) and complement fixation test (CF), and estimate the relative sensitivity and specificity of the dot-blot in comparison with these assessments. Fifty bovine blood serum samples have been used for the test standardization, and 1315 samples have been used for analysis and comparability between the assessments; the outcomes have been in contrast utilizing the Kappa indicator.

CC-401
B1260-5.1 10 mM (in 1mL DMSO)
EUR 258
Description: CC-401 is a specific inhibitor of JNK with Ki values of 25-50nM [1].CC-401 is a second generation ATP-competitive inhibitor of all three forms of JNK. It is selective against JNK over other kinases such as p38, ERK, IKK2 and ZAP70.

CC-401
B1260-50 50 mg
EUR 931
Description: CC-401 is a specific inhibitor of JNK with Ki values of 25-50nM [1].CC-401 is a second generation ATP-competitive inhibitor of all three forms of JNK. It is selective against JNK over other kinases such as p38, ERK, IKK2 and ZAP70.

JX 401
20-abx076645
  • EUR 384.00
  • EUR 1024.00
  • 10 mg
  • 50 mg
  • Shipped within 5-12 working days.

JX 401
B7140-1 1 mg
EUR 112

JX 401
B7140-10 10 mg
EUR 270

JX 401
B7140-5 5 mg
EUR 174

JX 401
B7140-50 50 mg
EUR 989

Compound 401
B7337-10 10 mg
EUR 224

Compound 401
B7337-25 25 mg
EUR 441

Compound 401
B7337-5 5 mg
EUR 180

PQ 401
A2033-25 25 mg
EUR 282
Description: PQ401 is a novel, potent inhibitor of IGF-IR with IC50 of 12?M [1].In human MCF-7 cells, PQ401 inhibited autophosphorylation of the IGF-IR with IC50 of 12 ?M and autophosphorylation of the isolated kinase domain of the IGF-IR with IC50 < 1?M.

PQ 401
A2033-5 5 mg
EUR 108
Description: PQ401 is a novel, potent inhibitor of IGF-IR with IC50 of 12?M [1].In human MCF-7 cells, PQ401 inhibited autophosphorylation of the IGF-IR with IC50 of 12 ?M and autophosphorylation of the isolated kinase domain of the IGF-IR with IC50 < 1?M.

PQ 401
A2033-5.1 10 mM (in 1mL DMSO)
EUR 173
Description: PQ401 is a novel, potent inhibitor of IGF-IR with IC50 of 12?M [1].In human MCF-7 cells, PQ401 inhibited autophosphorylation of the IGF-IR with IC50 of 12 ?M and autophosphorylation of the isolated kinase domain of the IGF-IR with IC50 < 1?M.

TCS 401
A4545-10 10 mg
EUR 293
Description: Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) (Ki values are 0.29, 59, 560, 1100, > 2000, > 2000 and > 2000 ?M for PTP1B, CD45 D1D2, PTP?, PTP? D1, SHP-1, PTP? D1 and LAR D1D2 respectively).

TCS 401
A4545-25 25 mg
EUR 572
Description: Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) (Ki values are 0.29, 59, 560, 1100, > 2000, > 2000 and > 2000 ?M for PTP1B, CD45 D1D2, PTP?, PTP? D1, SHP-1, PTP? D1 and LAR D1D2 respectively).

TCS 401
A4545-5 5 mg
EUR 189
Description: Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) (Ki values are 0.29, 59, 560, 1100, > 2000, > 2000 and > 2000 ?M for PTP1B, CD45 D1D2, PTP?, PTP? D1, SHP-1, PTP? D1 and LAR D1D2 respectively).

TCS 401
HY-12312 100mg
EUR 1290

Peptide 401
HY-12537 500ug
EUR 436

CC-401
HY-13022A 50mg
EUR 1153

Compound 401
HY-19341 10mM/1mL
EUR 186

CORM-401
HY-109804 5mg
EUR 234

BMZERO™, 500 ml
401 500 ml
EUR 105

CC-401 hydrochloride
A3287-10 10 mg
EUR 538
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-5 5 mg
EUR 321
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-5.1 10 mM (in 1mL DMSO)
EUR 348
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-50 50 mg
EUR 1497
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 (hydrochloride)
HY-13022 10mg
EUR 422

Fmoc-D-Ala-SASRIN resin (200-400 mesh, 0.5-0.8 mmol/g)
D-1425.0001 1.0g
EUR 236

Fmoc-D-Ala-SASRIN resin (200-400 mesh, 0.5-0.8 mmol/g)
D-1425.0005 5.0g
EUR 841

Boc-D-Ala-PAM resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1495.0001 1.0g
EUR 381

Boc-D-Ala-PAM resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1495.0005 5.0g
EUR 1421

Boc-D-Asn-PAM resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1570.0001 1.0g
EUR 122

Boc-D-Asn-PAM resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1570.0005 5.0g
EUR 381

Fmoc-D-Leu-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1765.0001 1.0g
EUR 261

Fmoc-D-Leu-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1765.0005 5.0g
EUR 925

Fmoc-D-Phe-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1770.0001 1.0g
EUR 261

Fmoc-D-Phe-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1770.0005 5.0g
EUR 925

Fmoc-D-Val-Wang resin (200-400 mesh, 0.6-0.9 mmol/g)
D-2465.0001 1.0g
EUR 176

Fmoc-D-Val-Wang resin (200-400 mesh, 0.6-0.9 mmol/g)
D-2465.0005 5.0g
EUR 611

Fmoc-D-Leu-Wang resin (200-400 mesh, 0.50-1.00 mmol/g)
D-2535.0001 1.0g
EUR 151

Fmoc-D-Leu-Wang resin (200-400 mesh, 0.50-1.00 mmol/g)
D-2535.0005 5.0g
EUR 515

Fmoc-D-Val-SASRIN resin (200-400 mesh, 0.5-0.8 mmol/g)
D-2690.0001 1.0g
EUR 145

Fmoc-D-Val-SASRIN resin (200-400 mesh, 0.5-0.8 mmol/g)
D-2690.0005 5.0g
EUR 477

Fmoc-D-Arg(Pmc)-Wang resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1560.0001 1.0g
EUR 261

Fmoc-D-Arg(Pmc)-Wang resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1560.0005 5.0g
EUR 961

Fmoc-D-Glu(OtBu)-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1775.0001 1.0g
EUR 170

Fmoc-D-Glu(OtBu)-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1775.0005 5.0g
EUR 587

Fmoc-D-Asn(Trt)-SASRIN resin (200-400 mesh, 0.3-0.6 mmol/g)
D-1780.0001 1.0g
EUR 454

Fmoc-D-Asn(Trt)-SASRIN resin (200-400 mesh, 0.3-0.6 mmol/g)
D-1780.0005 5.0g
EUR 1698

Fmoc-D-Lys(Boc)-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1785.0001 1.0g
EUR 309

Fmoc-D-Lys(Boc)-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1785.0005 5.0g
EUR 1143

Fmoc-D-Pen(Trt)-Wang resin (200-400 mesh, 0.25-0.55 mmol/g)
D-1870.0001 1.0g
EUR 381

Fmoc-D-Pen(Trt)-Wang resin (200-400 mesh, 0.25-0.55 mmol/g)
D-1870.0005 5.0g
EUR 1421

Fmoc-D-Trp(Boc)-Wang resin (200-400 mesh, 0.5-0.8 mmol/g)
D-1905.0001 1.0g
EUR 261

Fmoc-D-Trp(Boc)-Wang resin (200-400 mesh, 0.5-0.8 mmol/g)
D-1905.0005 5.0g
EUR 925

Fmoc-D-Cys(Trt)-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1985.0001 1.0g
EUR 454

Fmoc-D-Cys(Trt)-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-1985.0005 5.0g
EUR 1698

Fmoc-D-Arg(Pbf)-Wang resin (200-400 mesh, 0.50-1.00 mmol/g)
D-1995.0001 1.0g
EUR 334

Fmoc-D-Arg(Pbf)-Wang resin (200-400 mesh, 0.50-1.00 mmol/g)
D-1995.0005 5.0g
EUR 1251

Fmoc-D-Asp(OtBu)-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-2680.0001 1.0g
EUR 309

Fmoc-D-Asp(OtBu)-SASRIN resin (200-400 mesh, 0.4-0.7 mmol/g)
D-2680.0005 5.0g
EUR 1143

H-D-Val-2-chlorotrityl resin (200-400 mesh, 0.50-0.90 mmol/g)
D-2990.0001 1.0g
EUR 265

H-D-Val-2-chlorotrityl resin (200-400 mesh, 0.50-0.90 mmol/g)
D-2990.0005 5.0g
EUR 970

DCTN2 (1-401) Dynactin 2 (1-401 a.a.) Human Recombinant Protein
PROTQ13561 Regular: 10ug
EUR 317
Description: Dynactin 2 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 424 amino acids (1-401 a.a) and having a molecular mass of 46.6kDa.;DCTN2 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Fmoc-D-His(1-Trt)-SASRIN resin (200-400 mesh, 0.2-0.5 mmol/g)
D-1980.0001 1.0g
EUR 244

Fmoc-D-His(1-Trt)-SASRIN resin (200-400 mesh, 0.2-0.5 mmol/g)
D-1980.0005 5.0g
EUR 866

H-D-Arg(Pbf)-2-chlorotrityl resin (200-400 mesh, 0.50-0.90 mmol/g)
D-2940.0001 1.0g
EUR 265

H-D-Arg(Pbf)-2-chlorotrityl resin (200-400 mesh, 0.50-0.90 mmol/g)
D-2940.0005 5.0g
EUR 970

H-D-Cys(4-methoxytrityl)-2-chlorotrityl resin (200-400 mesh, 0.4-0.7 mmol/g)
D-2485.0001 1.0g
EUR 309

H-D-Cys(4-methoxytrityl)-2-chlorotrityl resin (200-400 mesh, 0.4-0.7 mmol/g)
D-2485.0005 5.0g
EUR 1143

Cellufine GCL-2000HF
21-401 500 ml
EUR 452

Cellufine MAX S-h
20-401 500 ml
EUR 1464

DIRECTPCR LYSIS REAGENT (EAR)
401-E 25 ml
EUR 141
Description: For use with ear pieces

pCMV-GFP-LC3 Expression Vector
CBA-401 100 µL
EUR 1036
Description: Expression vector contains a fusion of GFP and LC3. A separate GFP control vector is also included.

pAAV-Cre Control Vector
AAV-401 10 µg
EUR 566
Description: Use this control vector to co-transfect along with AAV packaging vectors to produce a recombinant AAV control.

Self-Sealing Sterilization Pouches, 2 3/4” x 9”
LC3048-401 20bx/CS
EUR 475

Self-Sealing Sterilization Pouches, 3 1/2” x 9”
LC3050-401 20bx/CS
EUR 489

pSMPUW-GFP-Puro Lentiviral Control Vector
LTV-401 10 µg
EUR 618
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus.

Recombinant (E.Coli) Streptokinase
RP-401 250 KU
EUR 347

50X TAE Buffer,1 Gallon, Refill Pack
T8050-401 1 Gal
EUR 261

5X TBE Buffer, 1 Gallon, Refill Pack
T8051-401 1 Gal
EUR 112

10X Tris-Glycine Native Buffer (Transfer buffer)
T8052-401 4X1L
EUR 165

10X Tris-Glycine SDS buffer
T8053-401 4X1L
EUR 172

TBS Buffer, 20X pH 7.4, 1 Gallon, Refill Pack
T8054-401 1 Gal
EUR 192

TBS Buffer, 10X , Refill Pack
T8057-401 1 Gal
EUR 182

AAV-1 Helper Free Packaging System
VPK-401 1 kit
EUR 972
Description: The AAV Helper Free System produces recombinant AAV containing your gene of interest without the need to use a helper adenovirus. The adenoviral genes required for proper AAV packaging are provided in the pHelper plasmid (E2A, E4 and VA RNA) or in the 293 packaging cells (E1).

C. difficile Toxin B (392 - 401)
5-00876 4 x 5mg Ask for price

Dynactin 2 (1-401 a.a.) Protein
20-abx261209
  • EUR 328.00
  • EUR 6397.00
  • EUR 230.00
  • 10 ug
  • 1 mg
  • 2 µg
  • Shipped within 5-10 working days.

JX 401 (p38 MAP kinase inhibitor)
SIH-454-10MG 10 mg
EUR 233
  • JX 401 is a potent and reversible inhibitor of p38?. Specifically, it binds MAPK p38?. JX 401 is cell permeable.
Description: The substance JX 401 is a p38 map kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (10 mg/ml).

JX 401 (p38 MAP kinase inhibitor)
SIH-454-50MG 50 mg
EUR 709
  • JX 401 is a potent and reversible inhibitor of p38?. Specifically, it binds MAPK p38?. JX 401 is cell permeable.
Description: The substance JX 401 is a p38 map kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (10 mg/ml).

C. difficile Toxin B (392 401) Peptide
20-abx266110
  • EUR 411.00
  • EUR 662.00
  • EUR 314.00
  • 10 mg
  • 25 mg
  • 5 mg
  • Shipped within 5-10 working days.

Recombinant MARV mat (aa 1-401) Protein
VAng-Wyb3500-1mgEcoli 1 mg (E. coli)
EUR 4738
Description: Methanothermobacter marburgensis (strain DSM 2133 / 14651 / NBRC 100331 / OCM 82 / Marburg) S-adenosylmethionine synthase protein, recombinant protein.

Recombinant MARV mat (aa 1-401) Protein
VAng-Wyb3500-500gEcoli 500 µg (E. coli)
EUR 3349
Description: Methanothermobacter marburgensis (strain DSM 2133 / 14651 / NBRC 100331 / OCM 82 / Marburg) S-adenosylmethionine synthase protein, recombinant protein.

Recombinant MARV mat (aa 1-401) Protein
VAng-Wyb3500-50gEcoli 50 µg (E. coli)
EUR 2291
Description: Methanothermobacter marburgensis (strain DSM 2133 / 14651 / NBRC 100331 / OCM 82 / Marburg) S-adenosylmethionine synthase protein, recombinant protein.

NATtrol Chlamydia trachomatis serotype D, External Run Control, Medium (6X1mL)
NATCT(D-UW3)-ERCM 6X1mL
EUR 401.52
  • What is the product classification?
  • NATtrol Chlamydia trachomatis serotype D, External Run Control, Medium is marked as RUO.
Description: Please contact Gentaur in order to receive the datasheet of the product.

D-D-D-D-D-D
5-01027 4 x 5mg Ask for price

D-D-D-D-D
5-01026 4 x 5mg Ask for price

At the top of standardization, it was established as optimum for the antigen obtained from Brucella abortus B19 after passing via a microorganism rupture course of, the blood serum samples diluted at 1:100, and the conjugate at 1:30,000. The comparability of the dot-blot outcomes with 2-ME confirmed Kappa index of 0.9939, sensitivity of 99.48%, and specificity 99.91%, with CF, Kappa index of 0.8226, sensitivity 100% and specificity 95.32%. Using the mix of the test outcomes 2-ME and CF to ascertain the true situation of the animal, the dot-blot confirmed relative sensitivity of 100%, and relative specificity of 99.91%. The evaluated test proved to be efficient and dependable, in addition to being simple to deal with and interpret the outcomes.

 

Categories: Blot Test

Related Posts

Blot Test

Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.

OBJECTIVE To decide the medical significance of the polymerase chain response (PCR)-reverse dot blot (RDB) human papillomavirus (HPV) genotyping assay in cervical most cancers screening. METHODS A complete of 10,442 women attending the Fujian Provincial Read more…